Insulet Corp. (PODD)
Healthcare · Medical - Devices · Data as of 2026-10-22
Bottom line
PODD is trading near its usual valuation, near its historical support zone, and recent volume suggests money flowing in. Historically, this combination has been a favourable starting point for further research. Past patterns are not a guarantee of future results.
Valuation — Priced about in line with its growth (Yellow)
For a fast-growing company like PODD (revenue is growing about 31% a year), we weigh next year's expected P/E of 23× against the 19% earnings growth analysts expect (a forward PEG of 1.22, 15 estimates). That is a fairly typical trade-off. Its current multiple sits around the 2nd percentile of its own last five years — toward the low end of its own range.
Price zones — Near its historical support zone (Green)
At $148.12, the stock is close to the lower end of its recent range. Over the past year PODD has traded between $126.40 and $354.88; its historical support zone sits near $140.45 and resistance near $182.91. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $126.40–$354.88 · 50-day average $140.45 · 200-day average $182.91
Money flow — Money is flowing in (Green)
Recent trading in PODD shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 1.3× volume on down days over the last 30 sessions.
Dividends & company facts
PODD doesn't pay a dividend, but it bought back $26 million of its shares in fiscal 2025, about 0.25% of its market value. Its share count fell 1.8% over the past year.
- Buybacks
- 0.25% (fiscal 2025)
- Shares, past year
- -1.8%
- Revenue, 12 months
- $3.1B
- Profit, 12 months
- $375M
- Employees
- 5,400
- CEO
- Ashley McEvoy
- Headquarters
- Acton, MA
- Listed since
- 2007 · NASDAQ
About the company
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes…
Related stocks
一句话结论
PODD 估值接近其惯常水平，接近其历史支撑区，近期成交量显示资金正在流入。从历史来看，这样的组合是一个值得进一步研究的有利起点。过去的形态并不能保证未来的结果。
估值 — 价格与其增长大致相称
对 PODD 这样的高增长公司（营收年增长约 31%），我们把它明年的预期市盈率 23× 与分析师预计的 19% 盈利增速放在一起看（前瞻 PEG 为 1.22，来自 15 份预测）。这是相当常见的一种取舍。它当前的估值倍数大约位于自身过去五年分布的第 2 百分位——处于自身区间的偏低位置。
价格区间 — 接近其历史支撑区
目前价格为 $148.12，接近其近期区间的下沿。过去一年 PODD 的价格在 $126.40 到 $354.88 之间波动；其历史支撑区在 $140.45 附近，阻力区在 $182.91 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 资金正在流入
PODD 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 1.3×。
股息与公司概况
PODD 不派发股息，但在 2025 财年回购了 2,570万美元 的股票，约占市值的 0.25%。其股数过去一年减少了 1.8%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.